Gilead’s Phase II trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of GS 9350, elvitegravir and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1, met its primary objective. The ongoing study of 71 HIV-infected, antiretroviral treatment-naïve adults compares the Quad with Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Based on 24-week data, efficacy of the Quad regimen met the s...